Ulcerative Colitis Nexus Letter for VA Disability Claims

Revised Framework (claims received or pending on or after May 19, 2024)

Under the revised schedule, DC 7323 directs that ulcerative colitis be rated under the inflammatory bowel disease criteria, the same framework used for Crohn's disease, on a 10 to 100 percent scale. The tiers turn on treatment intensity, hospitalization frequency, and impact on health and work, with the 100 percent level reserved for severe disease unresponsive to treatment that requires hospitalization at least once per year and produces inability to work or recurrent abdominal pain with specified associated findings.

Ulcerative colitis is one of the two primary forms of inflammatory bowel disease, a chronic condition in which the immune system attacks the lining of the colon. Unlike IBS, the diagnosis is structural: it is confirmed by colonoscopy and biopsy, and the disease runs in cycles of flare and remission. Typical onset falls in young adulthood, which is exactly the window most veterans are in uniform. Bowel symptoms noted during service and diagnosed as colitis years later are the same disease at two points in time, and a nexus opinion exists to say so explicitly.

Where the disease was not present in service, the claim usually runs through secondary service connection via the gut-brain-immune axis. Peer-reviewed research describes how chronic stress from conditions like PTSD contributes to immune dysregulation, increased intestinal permeability, and altered microbiome composition, mechanisms that can trigger or worsen inflammatory bowel disease. These opinions must do two things most denials show were never done: explain the pathophysiology rather than assert it, and address causation and aggravation as separate questions.

The rating framework depends on the claim date. Under the legacy criteria, DC 7323 rated ulcerative colitis at 10, 30, 60, or 100 percent on exacerbation frequency and constitutional impact, from moderate disease with infrequent exacerbations up to pronounced disease with marked malnutrition, anemia, and general debility. Effective May 19, 2024, ulcerative colitis is rated under the inflammatory bowel disease criteria, the same framework that rates Crohn's disease, on a 10 to 100 percent scale driven by treatment intensity, hospitalization frequency, and impact on health and work. Diagnoses under the revised IBD code must be confirmed by endoscopy or radiologic studies, and following colectomy or colostomy with persistent symptoms, the condition is rated under the IBD code or the large intestine resection code, whichever produces the higher evaluation.

Two evidentiary points decide most of these files. First, the disease is episodic and examinations are not. A C&P exam on a controlled day cannot capture flare frequency; the treatment record between appointments carries the rating. Second, under the legacy criteria, VA caselaw provides that a higher rating may not be denied based on relief provided by medication where the criteria do not contemplate medication effects, and the legacy DC 7323 contains no reference to medication. A file rated down because Humira is working may have been rated on the wrong question.